© 2024 WSKG

601 Gates Road
Vestal, NY 13850

217 N Aurora St
Ithaca, NY 14850

FCC LICENSE RENEWAL
FCC Public Files:
WSKG-FM · WSQX-FM · WSQG-FM · WSQE · WSQA · WSQC-FM · WSQN · WSKG-TV · WSKA
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

WSKG thanks our sponsors...

Pfizer-BioNTech COVID vaccine appears more than 90% effective in kids 5 to 11

NEW ORLEANS, LOUISIANA - AUGUST 12: Pharmacist LaChandra McGowan prepares a dose of the Pfizer COVID-19 vaccine at a clinic operated by DePaul Community Health Center on August 12, 2021 in New Orleans, Louisiana. Louisiana holds one of the nation’s lowest vaccination rates with just 38 percent of its residents fully-vaccinated. The state currently has the highest amount of COVID cases per capita in the U.S. over the last 14 days. (Photo by Mario Tama/Getty Images)
Pharmacist LaChandra McGowan prepares a dose of the Pfizer COVID-19 vaccine at a clinic operated by DePaul Community Health in New Orleans in August. Soon, children ages 5 to 11 could be eligible for Pfizer shots.

Pfizer and its partner BioNTech say their data supports authorization of their COVID-19 vaccine in kids 5 to 11. The Food and Drug Administration released the companies' briefing document Friday morning in a prelude to a meeting of expert advisers to the agency scheduled for Tuesday. The companies studied a 10 microgram vaccine dose in children ages 5 to 11, a third of the dose used for adults and older children. The lower dose was chosen to minimize side effects and because it still prompts a strong immune response, the companies said.In the main clinical trial conducted by the companies, the vaccine appeared to be more than 90% effective against symptomatic COVID-19No new safety problems were identified in the companies' studies. No cases of heart inflammation were observed in the main study, but only a few thousand children were included in the research, so that sort of rare problem wouldn't necessarily be detected. The antibody response to the vaccine was comparable to the one seen in people 16 to 25 years old. The FDA is preparing its own analysis, which is likely to be released later Friday. Copyright 2021 NPR. To see more, visit https://www.npr.org.